·       Patient-focused development: Telecan is expanding its digital offering to provide patients seekingmedical advice and treatment with an additional route to physician-led care.
‍

·       Improved access to care: The supplementary offering is designed to address patients’ differingneeds and provide greater flexibility in accessing a medical assessment.
‍

·       Strategic development: By expanding Telecan, Cantourage is strengthening its position indigital healthcare for medical cannabis and creating long-term growthopportunities.
‍

Cantourage Group SE (ISIN: DE000A3DSV01) is continuing the targeteddevelopment of its telemedicine platform Telecan. In addition to the existingvideo consultation service, the platform will offer a further digital,questionnaire-based route for physicians to review treatment requests. The aimis to provide patients with a corresponding medical need with access to physician-ledcare that is as straightforward and flexible as possible while maintainingmedical responsibility.
‍

Through this development, Cantourage is responding to evolvingrequirements for digital healthcare services while further strengtheningTelecan’s positioning in the German medical cannabis market.
‍

Patient-focused development of healthcareservices

Telecan has established itself as a digital point of contact forpatients seeking medical advice and, where appropriate, treatment with medicalcannabis.
‍

The additional digital access route is intended to offer both existingregistered patients and new patients another way to have their medicaltreatment needs assessed by a physician. The focus is not on use of theplatform itself, but on providing appropriate medical care tailored topatients’ needs.
‍

The supplementary access route is designed to accommodate differingpersonal and medical requirements and make the process of obtaining a medicalassessment more flexible. In doing so, Telecan is systematically building onits existing healthcare offering.
‍

Expanded digital care pathway

Under the new offering, patients can initially submit their medicalinformation through a structured digital questionnaire. A licensed physicianassesses each case individually, may ask follow-up questions or arrange anadditional consultation, and independently decides whether a prescription isappropriate. The offering is structured in accordance with the applicablemedical and legal requirements.
‍

In Cantourage’s view, this additional care pathway complements Telecan’sexisting services with a form of physician contact that is already establishedin digital healthcare.
‍

Paul Thies, Managing Director of Apsat GmbH(Telecan), comments: “By further developing Telecan, we aim to make it easierfor patients to access a qualified medical assessment. This additional digitalpathway expressly does not constitute automated prescribing. Every treatmentcase is reviewed individually by a licensed physician, who arranges directphysician-patient contact whenever medically or legally necessary. Weconsistently adhere to the applicable medical and regulatory requirements andhave developed the platform further so that we can also respond flexibly tofuture legislative changes. Our aim is to make meaningful use of digitalopportunities while ensuring high standards of medical quality and regulatorycompliance.”
‍

Strategic significance for Cantourage

Telecan is an important element of Cantourage’s strategic positioning inthe German medical cannabis market. The platform supports access to careprovided under physicians’ responsibility and contributes to the ongoingdevelopment of digital healthcare structures in this field.
‍

For Cantourage, this may indirectly create additional commercialopportunities in its pharmacy business. The company generates its productrevenue from the distribution of medical cannabis products to pharmacies,rather than from the telemedicine platform itself.
‍

Philip Schetter, CEO of Cantourage Group SE,comments: “By further developing Telecan, we are putting patients’ needs at thecentre of our efforts. Our goal is to provide people with a correspondingmedical need with modern, responsible access to physician-led care. At the sametime, we are strengthening Cantourage’s strategic position in the medicalcannabis market. We believe that the patient-focused development of digitalhealthcare services can also provide positive momentum for our business overthe long term.”
‍

About Cantourage

Cantourage is a leading European company engaged in the production anddistribution of medical cannabis preparations and pharmaceutical products. Withits experienced management team and “Fast Track Access” platform, Cantourageenables producers from around the world to gain faster, easier and morecost-effective access to the growing European medical cannabis market. To thisend, the company processes and distributes cannabis raw materials and extracts,consistently ensuring compliance with the highest European pharmaceuticalquality standards. Cantourage offers pharmaceutical-grade products across allrelevant market segments: dried cannabis flowers, extracts, dronabinol andcannabidiol. Cantourage has been listed on the Frankfurt Stock Exchange since11 November 2022 (ISIN: DE000A3DSV01).

‍